Read More Pharma Industry News Paradigm Biopharmaceuticals scores A$16m investment—Here’s what it means for osteoarthritis treatment Paradigm Biopharmaceuticals Ltd. (ASX: PAR) has secured a significant A$16 million in funding, positioning the company to launch… byPallavi MadhirajuDecember 9, 2024